Study of BGB-11417 for blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests BGB-11417 in people with certain bone-marrow (blood) cancers such as AML, MDS, or MDS/MPN. The goal is to find out how the medicine works and whether it can control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of AML (not acute promyelocytic leukemia), MDS, or MDS/MPN.
- Your general health is good enough (ECOG performance status 0–2).
- Your kidneys and liver work well enough for treatment (kidney filtering test usually ≥50 mL/min, or 30–49 mL/min in some less-fit AML patients).
- You are expected to live more than 12 weeks.
- You can follow the study plan (visits, tests, and treatments as required).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
This trial tests a new drug, S241656, alone or with other treatments, for people with specific types of blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have not responded to standard treatments or have come back.
This trial is testing a new drug called GLB-001 for people with certain blood cancers or bone marrow disorders that have not gotten better with standard treatments. The goal is to see if the drug is safe and how well it works.
This study tests a new drug (PBSS1113) combined with azacitidine for people with certain blood cancers (AML or high-risk MDS). The goal is to see if the combination is safe and effective.
This Phase 1 study tests APG-115 alone or with azacitidine or cytarabine in people whose acute myeloid leukemia (AML) or high-risk MDS has come back or hasn’t responded. The goal is to see safety and whether the treatment can work for these conditions.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.